Antimicrobial susceptibility of group B streptococci collected in two Belgian hospitals

Acta Clinica Belgica

Volumn 60, Issue 4, 2005, Pages 180-184

  Decoster, L ^a   Frans, J ^a   Blanckaert, H ^a   Lagrou, K ^a   Verhaegen, Jan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Clindamycin; Macrolides; Pregnancy; Streptococcus agalactiae; Susceptibility testing

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFOTAXIME; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; OXYTETRACYCLINE; PENICILLIN G; VANCOMYCIN;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BELGIUM; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREGNANCY; STREPTOCOCCUS AGALACTIAE; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECT; IN VITRO STUDY; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTICENTER STUDY; STREPTOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BELGIUM; COLONY COUNT, MICROBIAL; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 33644617021     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2005.032     Document Type: Article

References (21)

1. Wu J J, Lin K Y, Hsueh P R, Liu J W, Pan H I, Sheu S M. High incidence of erythromycin-resistant streptococci in Taiwan. Antimicrob Agents Chemother 1997; 41: 844-46.
2. Betriu C, Culebras E, Gomez M et al. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother 2003; 47: 1112-4.
3. Pearlman M D, Pierson C L, Faix R G. Frequent resistance of clinical group B Streptococci isolates to clindamycin and erythromycin. Obstet Gynecol 1998; 92: 258-61.
4. Andrews J I, Diekema D J, Hunter S K et al. Group B streptococci causing neonatal bloodstream infections: Antimicrobial susceptibility and serotyping. Results from the SENTRY centers in the Western Hemisphere. Am J Obst Gyn 2000; 4: 859-862.
5. Lin F-Y, Azimi P H, Weisman L E et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis 2000, 31: 76-9.
6. Murdoch D R, Reller L B. Antimicrobial susceptibilities of group B Streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob Agents Chemother 2001; 45: 3623-4.
7. De Azavedo J C S, McGavin M, Duncan C, Low D E, McGeer A. Prevalence and mechanisms of macrolide resistance in invasise and noninvasive group B Streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother 2001; 45: 3504-8.
8. Heelan J S, Hasenbein M E, McAdam A J. Resistance of group B Streptococcus to selected antibiotics, including erythromycin and clindamycin. J Clin Microbiol 2004; 42: 1263-4.
9. Ruess M, Müller U, Sander A, Berner R. Antimicrobial susceptibility patterns of Streptococcus agalactiae in a German university hospital. Scand J Infect Dis 2000; 32: 623-6.
10. Fitoussi F, Loukil C, Gros I et al. Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob Agents Chemother 2001; 45: 1889-91.
11. De Mouy D, Cavallo J-D, Leclerq R, Fabre R. Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob Agents Chemother 2001; 45: 2400-2.
12. Aracil B, Minambres M, Oteo J, de la Rosa M, Gomez-Garces J L, Alos J I. Susceptibility of strains of Streptococcus agalactiae to macrolides and lincosamides, phenotype patterns and resistance genes. Clin. Microb Infect 2002; 8: 745-8.
13. Alhambra A, Gomez-Garces J L, Alos J I. Susceptibility of Streptococcus agalactiae isolates from blood and urine to 18 widely used and recently marketed antibiotics. Clin Microbiol Infect 2004; 10: 267-8.
14. Hsueh P-R, Teng L-J, Lee L-N, Ho S-W, Yang P-C, Luh K-Y. High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan. Antimicrob Agents Chemother 2001; 45: 3205-8.
15. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance and their clinical implications. Clin Infect Dis 2002; 34: 482-92.
16. Blanckaert H, Frans J, Bosteels J, Hanssens M, Verhaegen J. Optimisation of prenatal Group B Streptococcal screening: lessons from practice in two Belgian hospitals. Eur J Clin Microbiol Infect Dis 2003; 22: 619-21.
17. thed. NCCLS document M7-A6.
18. Seppälä H, Nissinen A, Yu Q, Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993; 32: 885-91.
19. Philipson A, Sabath L D, Charles D. Transplacental passage of erythromycin and clindamycin. N Eng J Med 1973; 288: 1219-21.
20. Weinstein A J, Gibbs R S, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 1976; 124: 688-91.
21. Fernandez M, Hickman M E, Baker C J. Antimicrobial susceptibilities of group B Streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother 1998; 42: 1517-9.